MCY vs. BMY
Compare and contrast key facts about Mercury General Corporation (MCY) and Bristol-Myers Squibb Company (BMY).
Performance
MCY vs. BMY - Performance Comparison
Loading graphics...
MCY vs. BMY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
MCY Mercury General Corporation | -7.42% | 44.10% | 82.26% | 13.59% | -32.61% | 6.18% | 13.44% | -1.23% | 1.68% | -7.23% |
BMY Bristol-Myers Squibb Company | 15.79% | 0.11% | 15.81% | -26.14% | 18.98% | 2.88% | 0.41% | 27.74% | -12.90% | 7.71% |
Fundamentals
MCY:
$4.81B
BMY:
$125.99B
MCY:
$9.77
BMY:
$3.46
MCY:
8.88
BMY:
17.84
MCY:
0.12
BMY:
1.02
MCY:
0.80
BMY:
2.61
MCY:
1.99
BMY:
2.26
MCY:
$5.99B
BMY:
$48.19B
MCY:
$720.33M
BMY:
$30.43B
MCY:
$490.06M
BMY:
$13.82B
Returns By Period
In the year-to-date period, MCY achieves a -7.42% return, which is significantly lower than BMY's 15.79% return. Over the past 10 years, MCY has outperformed BMY with an annualized return of 8.87%, while BMY has yielded a comparatively lower 2.90% annualized return.
MCY
- 1D
- -1.57%
- 1M
- -4.91%
- YTD
- -7.42%
- 6M
- 4.27%
- 1Y
- 57.04%
- 3Y*
- 43.33%
- 5Y*
- 10.65%
- 10Y*
- 8.87%
BMY
- 1D
- 1.78%
- 1M
- -0.98%
- YTD
- 15.79%
- 6M
- 33.50%
- 1Y
- 8.90%
- 3Y*
- 0.70%
- 5Y*
- 3.49%
- 10Y*
- 2.90%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MCY vs. BMY — Risk / Return Rank
MCY
BMY
MCY vs. BMY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Mercury General Corporation (MCY) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| MCY | BMY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.96 | 0.31 | +1.65 |
Sortino ratioReturn per unit of downside risk | 2.52 | 0.64 | +1.88 |
Omega ratioGain probability vs. loss probability | 1.34 | 1.08 | +0.26 |
Calmar ratioReturn relative to maximum drawdown | 4.44 | 0.25 | +4.20 |
Martin ratioReturn relative to average drawdown | 11.80 | 0.39 | +11.41 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| MCY | BMY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.96 | 0.31 | +1.65 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.31 | 0.15 | +0.17 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.28 | 0.12 | +0.16 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.44 | 0.35 | +0.09 |
Correlation
The correlation between MCY and BMY is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
MCY vs. BMY - Dividend Comparison
MCY's dividend yield for the trailing twelve months is around 1.46%, less than BMY's 4.03% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
MCY Mercury General Corporation | 1.46% | 1.35% | 1.91% | 3.40% | 5.57% | 4.77% | 4.83% | 5.16% | 4.84% | 4.66% | 4.12% | 5.31% |
BMY Bristol-Myers Squibb Company | 4.03% | 4.60% | 4.24% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% |
Drawdowns
MCY vs. BMY - Drawdown Comparison
The maximum MCY drawdown since its inception was -68.83%, roughly equal to the maximum BMY drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for MCY and BMY.
Loading graphics...
Drawdown Indicators
| MCY | BMY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -68.83% | -72.03% | +3.20% |
Max Drawdown (1Y)Largest decline over 1 year | -13.00% | -25.79% | +12.79% |
Max Drawdown (5Y)Largest decline over 5 years | -55.28% | -47.67% | -7.61% |
Max Drawdown (10Y)Largest decline over 10 years | -55.28% | -47.67% | -7.61% |
Current DrawdownCurrent decline from peak | -9.47% | -12.07% | +2.60% |
Average DrawdownAverage peak-to-trough decline | -18.85% | -22.40% | +3.55% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.89% | 16.06% | -11.17% |
Volatility
MCY vs. BMY - Volatility Comparison
The current volatility for Mercury General Corporation (MCY) is 6.27%, while Bristol-Myers Squibb Company (BMY) has a volatility of 6.68%. This indicates that MCY experiences smaller price fluctuations and is considered to be less risky than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| MCY | BMY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.27% | 6.68% | -0.41% |
Volatility (6M)Calculated over the trailing 6-month period | 19.57% | 19.39% | +0.18% |
Volatility (1Y)Calculated over the trailing 1-year period | 29.25% | 28.61% | +0.64% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 34.02% | 23.68% | +10.34% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 31.73% | 25.08% | +6.65% |
Financials
MCY vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Mercury General Corporation and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
MCY vs. BMY - Profitability Comparison
MCY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Mercury General Corporation reported a gross profit of 0.00 and revenue of 1.54B. Therefore, the gross margin over that period was 0.0%.
BMY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a gross profit of 6.24B and revenue of 12.50B. Therefore, the gross margin over that period was 49.9%.
MCY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Mercury General Corporation reported an operating income of 0.00 and revenue of 1.54B, resulting in an operating margin of 0.0%.
BMY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported an operating income of 1.47B and revenue of 12.50B, resulting in an operating margin of 11.8%.
MCY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Mercury General Corporation reported a net income of 202.55M and revenue of 1.54B, resulting in a net margin of 13.2%.
BMY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Bristol-Myers Squibb Company reported a net income of 1.09B and revenue of 12.50B, resulting in a net margin of 8.7%.